Sushil Patel

Notable Quotes

Patel has said the durable responses seen in IGNYTE reflect a real benefit for patients who have run out of options.

from FDA weighs Replimune's melanoma immunotherapy RP1 · Updated 3 hours ago

Stories

FDA weighs Replimune's melanoma immunotherapy RP1

Rule Changes

Leading the company through its third attempt at FDA approval

Patients with advanced melanoma that keeps growing after standard immunotherapy have almost nothing left to try. Replimune wants to sell them a virus that is injected straight into tumors. On July 30, an FDA expert panel voted on whether the company's trial data are solid enough to prove the drug works.

Updated 3 hours ago